Brintellix Label Gives Lundbeck Ground For Tolerability Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.